Drug Trial Radar · NCT07722728
A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Aug 2026
Primary completion
Aug 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Bostal Drug Delivery Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is to evaluate the pharmacokinetic profile of B2227 Extended-Release Injectable Suspension against Vraylar® Cariprazine capsules of AbbVie Inc. in participants with schizophrenia.
Conditions
- Schizophrenia
Interventions
30 mg B2227Drug
Single-dose; Subcutaneous
70 mg B2227Drug
Single-dose; Subcutaneous
150 mg B2227Drug
Single-dose; Subcutaneous
Vraylar® 1.5 mgDrug
Multiple-dose, Oral
Vraylar® 3.0 mgDrug
Multiple-dose, Oral
Vraylar® 4.5 mgDrug
Multiple-dose, Oral
Vraylar® 6.0 mgDrug
Multiple-dose, Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: Pre-dose to 190 days post-dose
- TmaxTime frame: Pre-dose to 190 days post-dose
- AUC0-lastTime frame: Pre-dose to 190 days post-dose
- AUC0-infinityTime frame: Pre-dose to 190 days post-dose
- T1/2Time frame: Pre-dose to 190 days post-dose
- KelTime frame: Pre-dose to 190 days post-dose
- Vd/FTime frame: Pre-dose to 190 days post-dose
- MRTTime frame: Pre-dose to 190 days post-dose
- AUC_%Extrap_obsTime frame: Pre-dose to 190 days post-dose
- Cmax,ssTime frame: Pre-dose to 57 days post-dose
- Cmin,ssTime frame: Pre-dose to 57 days post-dose
- Cavg,ssTime frame: Pre-dose to 57 days post-dose
- AUC24hTime frame: Pre-dose to 57 days post-dose
- FluctuationTime frame: Pre-dose to 57 days post-dose
- SwingTime frame: Pre-dose to 57 days post-dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.